Use of product listing agreements by Canadian provincial drug benefit plans

The use of confidential negotiated agreements between pharmaceutical manufacturers and drug plans that support reimbursement of some products has emerged as a global pricing tool, with associated benefits and drawbacks. This study looks at the frequency of contract use by provincial drug benefit plans and makes recommendations for moving forward within this pricing paradigm.